论文部分内容阅读
目的探讨吉西他滨联合多西他赛治疗非小细胞肺癌的临床效果。方法所选的80例肺癌患者均为本院2011年7月~2012年7月期间收治患者,上述患者随机分为观察组和对照组。对照组患者第1天给予多西他赛联合顺铂(75 mg/m2),3个疗程后第1天、第8天给药吉西他滨。观察组患者在第1天、第8天、第15天给予多西他赛和顺铂(25 mg/m2),3个疗程;3个疗程后,给予吉西他滨,具体用法同对照组。分析两组化疗效果。结果观察组完全缓解和部分缓解所致比例与对照组比较,差异无统计学意义(P<0.05)。观察组Ⅲ、Ⅳ级中性粒细胞减少发生率低于对照组,差异有统计学意义(P<0.05)。观察组和对照组恶心呕吐、肝肾毒性、疼痛、口腔炎等不良反应发生情况差异无统计学意义(P<0.05)。结论吉西他滨联合多西他赛治疗非小细胞肺癌疗效显著,通过改变疗程有助于减少不良反应,值得借鉴。
Objective To investigate the clinical efficacy of gemcitabine and docetaxel in the treatment of non-small cell lung cancer. Methods Selected 80 cases of lung cancer patients were admitted to our hospital from July 2011 to July 2012, the above patients were randomly divided into observation group and control group. Patients in the control group received docetaxel plus cisplatin (75 mg / m2) on day 1 and gemcitabine on day 1 and 8 after 3 courses of treatment. Patients in the observation group were given docetaxel and cisplatin (25 mg / m2) on the first day, the eighth day and the 15th day for three courses of treatment. Gemcitabine was given after three courses of treatment, and the specific usage was the same as that of the control group. Analysis of two groups of chemotherapy. Results The proportion of complete remission and partial remission caused by observation group was not significantly different from that of control group (P <0.05). The incidence of grade Ⅲ and Ⅳ neutropenia in observation group was lower than that in control group, with statistical significance (P <0.05). Nausea and vomiting, liver and kidney toxicity, pain, stomatitis and other adverse reactions in the observation group and the control group had no significant difference (P <0.05). Conclusion Gemcitabine combined with docetaxel in the treatment of non-small cell lung cancer has a significant effect, which is worth learning from by changing the course of treatment to reduce adverse reactions.